The potential interplay between severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and treatment with immune-checkpoint inhibitors (ICIs) of patients with cancer is presently unknown \[[@bib1]\]. In this context, the increasing spreading of the coronavirus (COVID-19) pandemic does not help; in fact, major health resources are being redirected to counteract the pandemic \[[@bib2]\], raising the concrete risk to hamper cancer care significantly \[[@bib3]\]. As a result, the COVID-19 status of patients with cancer is generally not evaluated at the beginning and/or in the course of their medical treatment. In addition, the vast majority of patients with cancer receive therapy on an out-patients basis; thus, asymptomatic COVID-19 positive patients are generally free to access the Oncology Units, representing a major challenge for the possible transmission of SARS-CoV-2 to hospital personnel. On the other hand, these very same patients are challenged with the potential risk that ICI therapy may exacerbate the clinical course of their COVID-19 infection and/or that COVID-19 infection may worsen ICI-related side effects. In this composite and potentially cross-interfering scenario, sharing with the oncology community initial observations, even on a limited number of cases, may support treating physicians in their daily practice.

On March 6, an asymptomatic, 74-years-old male, Eastern Cooperative Oncology Group (ECOG) PS0, who was diagnosed with a metastatic cutaneous melanoma on November 2015 (patient 1), accessed our outpatient clinic with normal clinical and bio-humoural parameters to receive his 83rd cycle of an anti--PD-1 monoclonal antibody (mAb), being in partial objective response since June 2016. Worth mentioning, he had undergone right nephrectomy for a pT1N0M0 renal cell carcinoma on February 2016, and on October 2019 he had received a gastric wedge resection for a low-risk GIST. On March 16, the patient was admitted to the emergency room at a different hospital with a 4 days history of fever \>38.0 °C, mild dyspnoea and cough and oxygen saturation of 94%. Routine nasopharyngeal and oropharyngeal swabs revealed SARS-CoV-2 infection, and the patient was therefore hospitalized ([Fig. 1](#fig1){ref-type="fig"} ). Computed tomography (CT) scans revealed a bilateral pneumonitis, and laboratory tests were compatible with COVID-19 infection ([Fig. 1](#fig1){ref-type="fig"}) \[[@bib4],[@bib5]\]. The local protocol for COVID-19 infection was activated, and the patient was treated with oral azothromycin, darunavir/ritonavir, hydroxychloroquine and oxygen therapy. On March 24, lymphocyte count reached the nadir (i.e., 650 × 10^−9^U/L), and on April 2, the patient was discharged being asymptomatic, with normal blood values, and with two subsequent swabs testing negative for SARS-CoV-2 infection ([Fig. 1](#fig1){ref-type="fig"}). Being cured from COVID-19 infection ICI therapy will be reactivated.Fig. 1**COVID-19 assessments and bio-humoural parameters of treated patients.** SARS-CoV-2 infection was assessed by real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) testing positive (★) or negative (✪). Reference laboratory values for patient 1∗(C-reactive protein \<1.00; WBC: 4.000--10.000: ALC: 900--4500 and glucose: 70--110) and patient 2∗∗ (C-reactive protein 0.00--5.00; WBC: 4.000--11.000: ALC: 1000--3700 and glucose: 70--110).Fig. 1

On March 18, an asymptomatic, 51-years-old female, ECOG PS0, receiving adjuvant therapy for a locally advanced cutaneous melanoma surgically removed on July 2019 (patient 2), was admitted to our outpatient clinic with normal clinical and bio-humoural parameters to receive her 11th cycle of an anti--PD-1 mAb. Noteworthy, being the patient an MD, she had tested negative for SARS-CoV-2 infection on March 11 following a professional exposure to COVID-19. On March 19, the patient called our clinic referring asthenia, nausea, fever \>38.0 °C, headache and oxygen saturation of 98%. Owing to the persistence of the clinical symptoms, on March 25 nasopharyngeal and oropharyngeal swabs were performed, confirming SARS-CoV-2 infection ([Fig. 1](#fig1){ref-type="fig"}). Owing to the mildness of referred symptoms, and in accordance with the local protocol, the patient did not receive treatment for COVID-19 infection and was quarantined at home. On March 30, she referred improvement of clinical symptoms, while bio-humoural parameters normalized on April 3 ([Fig. 1](#fig1){ref-type="fig"}). Two subsequent swabs tested negative on April 3 and 4 for SARS-CoV-2 infection ([Fig. 1](#fig1){ref-type="fig"}); thus, the patient was considered cured from COVID-19 and she will resume ICI therapy shortly.

These two cases are representative of potential clinical scenarios with whom oncologists can be faced in their daily practice due to the COVID-19 pandemic. Undoubtedly, no general conclusion can be drawn from the positive outcome of these two patients on the reciprocal interplay between ICI therapy and SARS-CoV-2 infection. Nevertheless, these findings seem to suggest that treatment with ICI is a doable approach during the COVID-19 pandemic, and that SARS-CoV-2 infection does not seem to represent an obstacle to grant patients with cancer the best treatment in accordance with their clinical setting.
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